rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TCRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tscan Therapeutics earnings matched, revenue fell short of estimates
      Nov 12Investing.comTCRX
      TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

      Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumors Advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates for solid tumors through IND-enabling studies; on track to dose first patient in Q4 2027 Paused further enrollment in Phase 3 ALLOHA-2™ study of TSC-101; allowing data to mature and actively seeking strategic partners Cash and cash equivalents fund operations into the fourth quarter of 2027 WALTHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWI

      Nov 12Yahoo FinanceTCRX
      TScan Therapeutics Announces Executive Departures Amid Reorganization

      Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailTCRX
      TScan Therapeutics announces retention program for key executives
      Sep 11Investing.comTCRX
      H.C. Wainwright downgrades Tscan stock rating on restructuring
      Sep 8Investing.comTCRX
      TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow (NASDAQ:TCRX) 2026-09-04
      Sep 4Seeking AlphaTCRX
      Crude Oil Moves Higher; US Factory Orders Rise In July
      Sep 2BenzingaCRDOPPBTTCRX
      TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
      Sep 2BenzingaSLNTCRX
      Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift
      Sep 2Investing.comTCRX
      Why is TScan Therapeutics stock collapsing today?
      Sep 2Investing.comTCRX
      TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

      TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies.

      Sep 2Yahoo FinanceTCRX
      TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

      Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners Workforce reduction of approximately 75% and strategic

      Sep 2Yahoo FinanceTCRX
      TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

      11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism...

      Aug 30BarchartTCRX
      Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

      Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...

      Aug 26Yahoo FinanceAMGNTCRX

      This is the newest page. Registered accounts read further back.